Journals / Van Tıp Dergisi / 2022 / Cilt: 29 - Sayı: 4

Relationship of Lysosomal Storage Diseases (LSD) with Autophagy

Lizozomal Depo Hastalıklarının Otofaji ile İlişkisi

Pages
445–453
Publication Date
2022-11-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the general mechanisms of the relationship between lysosomal storage diseases and autophagy were evaluated toge ther with treatment approaches.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lysosomes are organelles that break down damaged components or structures that have completed their task in the cell by the hydrolytic enzymes they contain and take part in the last step of the autophagic pathway.
📊
Key Findings & Data:To date, more than 70 LDHs have been identified.
💡
Conclusion & Impact:In this review, the general mechanisms of the relationship between lysosomal storage diseases and autophagy were evaluated toge ther with treatment approaches.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lysosomes are organelles that break down damaged components or structures that have completed their task in the cell by the hydrolytic enzymes they contain and take part in the last step of the autophagic pathway. Autophagy, an evolutionarily conserved lysosomal pathway, is activated under stress conditions such as amino acid starvation, accumulation of unfolded proteins, or viral infection. The main task of autophagy is to remove dama ged proteins, or ganelles and microorganisms that constitute the source of infection. During this degradation mechanism, au tophagosomes are formed as a result of the interaction of ly sosomes and aut ophagic vesicles carrying damaged proteins, and this formation is tightly controlled by cellular mechanisms. Damage during this interaction can disrupt cellular homeostasis and interfere with the survival of the organism. Lysosomal Storage Diseases (LDH) is one of the most common human genetic diseases that develop because of mutations on genes encoding lysosomal enzymes. To date, more than 70 LDHs have been identified. LDH is mainly caused by functional disorders of enzymes or lysosome-associated proteins in lysosomes. These disorders may cause undigested macromolecules to accumulate in the cells, compromising the proper functioning of the organs in which they are located. LDH can cause many systemic damages, especially in the nervous system, skeletal system, and reticuloendothelial system, especially in the early stages of the disease. Modulation and reactivation of autophagy is considered a new therapeutic approach for LDH. In this review, the general mechanisms of the relationship between lysosomal storage diseases and autophagy were evaluated toge ther with treatment approaches.

Özet

Lizozomlar, hücredeki hasarlı bileşenleri veya görevini tamamlamış yapıları, içerisinde barındırdığı hidrolitik enzimler sayesinde parçalayan organellerdir ve otofajik yolağın son basamağında görev al ırlar. Evrimsel olarak korunmuş bir lizozomal yolak olan ot ofaji, amino asit açlığı, katlanmamış proteinlerin birikimi veya viral enfeksiyon gibi stres koşullarında etkinleşir. Otofajinin temel görevi, hasarlı proteinleri, organelleri ve en feksiyon kaynağını oluşturan mikroorganizmaları ortadan kaldırmaktır. Bu parçalanma mekanizması sırasında, lizozomlarla hasarl ı proteinleri taşıyan otofajik veziküllerin etkileşmesi sonucunda otofagozomlar oluşur ve bu olu şum hücresel mekanizmalar ile s ıkı bir şekilde kontrol alt ında tutulmaktadır. Bu etkileşim sırasında meydana gelen bir hasar, hücresel homeostazı bozabilir ve organizmanın hayatta kalmasına engel teşkil edebilir. Lizozomal Depo Hastalıkları (LDH), lizozomal enziml eri kodlayan genlerde oluşan mutasyonlar sonucu geli şen ve oldukça sık görülen insan genetik hastalıklarından biridir. Şimdiye kadar, 70’ten fazla LDH tanımlanmıştır. LDH esas olarak lizozomlardaki enzimlerin veya lizozomla ilişkili proteinlerin işlevsel bozukluklarından kaynaklanır. Meydana gelen bu bozukluklar, sindirilmemiş makromoleküllerin hücrelerde birikmesine yol açarak, bulundukları organların i şlevlerinin düzgün bir şekilde sürdürülmesini tehlikeye sokabilir. LDH, özellikle hastalığın erken evrelerinde başta sinir sistemi olmak üzere iskelet sistemi ve retiküloendotelyal sistemde birçok sistemik hasara neden olabilir. Otofajinin modülasyonu ve yeniden aktivasyonu LDH için yeni bir terapötik yaklaşım olarak kabul edilir. Bu derlemede lizozomal depo hastalıkları ve otofaji arasındaki ilişkinin genel mekanizmaları, tedavi yaklaşımlarıyla birlikte değerlendirilmiştir.

🔖

Cite This Article

Keskin, S., Alkaç, İ. M., Çerçi, B. (2022). Relationship of Lysosomal Storage Diseases (LSD) with Autophagy. Van Tıp Dergisi, Cilt: 29 - Sayı: 4, 445–453. https://ajindex.com/articles/655531

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol 2007; 8 (8): 622-632
  2. Lieberman AP, Puertollano R, Raben N, et al. Autophagy in lysosomal storage disorders. Autophagy 2012; 8 (5):719-730
  3. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991; 60(1):257-280
  4. Mashima, R., Okuyama, T. and Ohira, M. Biomarkers for Lysosomal Storage Disorders with an Emphasis on Mass Spectrometry. Int J Mol Sci 2020; 21(8), 2704
  5. Skotland T, Sagini K, Sandvig K, Llorente A. An emerging focus on lipids in extracellular vesicles. Adv Drug Deliver Rev 2020; 159: 308-321
  6. Leal AF, Espejo-Mojica AJ, Sánchez OF, Ramírez CM, Reyes LH, Cruz JC, et al. Lysosomal storage diseases: current therapies and future alternatives. J Mol Med 2020; 98(7): 931-946
  7. Ward C, Martinez-Lopez N, Otten EG, Carroll B, Maetzel D, Singh R, et al. Autophagy, lipophagy and lysosomal lipid storage disorders. BBA-Mol Cell Biol L 2016;1861(4): 269-284
  8. Eskelinen EL, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. BBA-Mol Cell Res 2009;1793(4): 664-673
  9. Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder- Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford Pharma Genesis; 2006
  10. Winchester B. Laboratory diagnosis of lysosomal storage dise ases. In: Metha A, Winchester B, editors. Lysosomal Storage Disorders: A Practical Guide. John Wiley & Sons, Ltd; 2012. p. 20-28
  11. Mehta A, Beck M, Linhart A, Sunder- Plassmann G, Widmer U. History of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006
  12. Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics 2011;5(3):1-4
  13. Palmieri M, Pal R, Nelvagal HR, Lotfi P, Stinnett GR, Seymour ML, Chaudhury A et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun 2017;8(1):1-9
  14. Bobillo Lobato J, Jiménez Hidalgo M, Jiménez Jiménez LM. Biomarkers in lysosomal storage diseases. Diseases 2016;4(4): 40
  15. Seranova E, Connolly KJ, Zatyka M, Rosenstock TR, Barrett T, Tuxworth RI, Sarkar S. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem 2017;61(6): 733- 749. 16.